Evidence map›Paper›PMID 30657336›Full record

ArticleDiabetes technology & therapeutics2019

State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016-2018.

Nicole C Foster, Roy W Beck, Kellee M Miller, Mark A Clements, Michael R Rickels, Linda A DiMeglio, David M Maahs, William V Tamborlane, Richard Bergenstal, Elizabeth Smith and 2 more

Erratum issued 8 registry-linked trialsOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes technology & therapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 8 registered trials, which are not on this map. Cited by 946 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
946citing papers in PubMed, 10 pooled it
169.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05478707 phase2recruitingstarted 2023, after this paper: background citation

Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes

Ran2023Enrolled47Registered outcomes5Posted comparisons0ConditionsDiabetes Mellitus, Type 1, Endothelial DysfunctionArmsDulaglutide, Placebo
PMID 29310645PMID 24742660PMID 22732108PMID 27295427PMID 27436611PMID 27633186PMID 29371269PMID 17711996PMID 19654321PMID 19672102PMID 20339920PMID 20739685other papers from this trial
Open the trial in the graph
NCT07284511 phase2 / phase3recruitingstarted 2026, after this paper: background citation

Fully Closed-Loop Glucose Control in Adults With Type 1 Diabetes Using Tirzepatide: a Randomized, Multi-center, Open-label, Non-inferiority, Parallel Trial

Ran2026Enrolled105Registered outcomes35Posted comparisons0ConditionsT1D, T1DM, T1DM - Type 1 Diabetes Mellitus, Type 1 DiabetesArmsCarbohydrate Counting, No Meal Announcement, Tandem Control-IQ Automated Insulin Delivery System (with Dexcom G7 CGM), Tirzepatide
PMID 39745353PMID 39601745PMID 31539622PMID 29246950PMID 27295427PMID 27633186PMID 34170647PMID 27621531PMID 31189511PMID 31902063PMID 34047449PMID 35733769other papers from this trial
Open the trial in the graph
NCT05000021 naactive not recruitingnot on this mapstarted 2022, after this paper: background citation

Reducing Diabetes Distress Using Cognitive Behavioral Therapy in Young Adults With Type 1 Diabetes

TypeinterventionalSponsorAlbert Einstein College of MedicineRan2022 to 2027Enrolled96ConditionsType 1 DiabetesArmsCognitive Behavioral Therapy for Diabetes Distress (CBT-DD) with Continuous Glucose Monitoring, Continuous Glucose Monitoring (CGM)
NCT05031429 nacompletednot on this mapstarted 2022, after this paper: background citation

Time Limited Eating in New-Onset Type 1 Diabetes: Feasibility, Acceptability, and Effect on β-cell Function

TypeinterventionalSponsorChildren's Hospital Los AngelesRan2022 to 2023Enrolled12ConditionsType 1 DiabetesArmsTime Limited Eating
NCT05211869 nacompletednot on this mapstarted 2022, after this paper: background citation

T1DTechCHW: Enhancing the Community Health Worker (CHW) Model to Promote Diabetes Technology Use in Young Adults From Underrepresented Minority Groups (YA-URMs) With Type 1 Diabetes (T1D)

TypeinterventionalSponsorAlbert Einstein College of MedicineRan2022 to 2025Enrolled119ConditionsDiabetes, Type 1 Diabetes, Young Adult, Diabetes MellitusArmsT1D-CATCH
NCT06390371 naactive not recruitingnot on this mapstarted 2024, after this paper: background citation

Spotlight AQ Randomized Controlled Trial of the Spotlight AQ Survey Platform to Evaluate Its' Efficacy and Applicability in a Clinic Setting.

TypeinterventionalSponsorChildren's Mercy Hospital Kansas CityRan2024 to 2026Enrolled60ConditionsType 1 Diabetes MellitusArmsSpotlight AQ Survey platform
NCT06427421 narecruitingnot on this mapstarted 2025, after this paper: background citation

Characterization of Autoreactive Regulatory and Conventional CD4 T Cells in Recent Onset Type 1 Diabetes and Control Individuals

TypeinterventionalSponsorAssistance Publique - Hôpitaux de ParisRan2025 to 2027Enrolled80ConditionsType 1 DiabetesArmsFrequency of Treg and Teffs, Phenotype of Treg and Teffs, RNA seq analysis, HLA typing, beta-cell autoantibody dosage
NCT07185555 narecruitingnot on this mapstarted 2025, after this paper: background citation

Applying Very Low Calorie Ketogenic Diet to the Treatment of Obesity in People With Type 1 Diabetes on Intensive Insulin Therapy Using Automated Insulin Delivery System

TypeinterventionalSponsorAzienda Ospedaliero-Universitaria Consorziale Policlinico di BariRan2025 to 2026Enrolled14ConditionsType 1 Diabetes (T1D), Obesity (Disorder)ArmsVLEKT
3 · Its place in the literature

Who cites it

946 citing papers in PubMed, 10 syntheses or guidelines pooled it, 1,836 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

886 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Nicole C Foster1 Jaeb Center for Health Research, Tampa, Florida.
Roy W Beck1 Jaeb Center for Health Research, Tampa, Florida.
Kellee M Miller1 Jaeb Center for Health Research, Tampa, Florida.
Mark A Clements2 Endocrine/Diabetes Department, Children's Mercy Hospital, Kansas City, Missouri.
Michael R Rickels3 Rodebaugh Diabetes Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.
Linda A DiMeglio4 Department of Pediatrics, Indiana University School of Medicine, Indianapolis Indiana.
David M Maahs5 Department of Pediatrics-Endocrinology, Stanford University, Stanford, California.
William V Tamborlane6 Pediatric Endocrinology and Diabetes, Yale University School of Medicine, New Haven, Connecticut.
Richard Bergenstal7 International Diabetes Center Park Nicollet, Minneapolis, Minnesota.
Elizabeth Smith1 Jaeb Center for Health Research, Tampa, Florida.
Beth A Olson7 International Diabetes Center Park Nicollet, Minneapolis, Minnesota.
Satish K Garg8 Barbara Davis Center for Childhood Diabetes, University of Colorado Denver, Aurora, Colorado.
Jaeb Center for Health Research · USPark Nicollet Clinic · USUniversity of Colorado Denver · US

Funding

Stanford Islet Research CoreP30DK116074 · NIDDK · STANFORD UNIVERSITY · PI Seung K Kim · 2017 to 2026
$19.5M
NIDDK NIH HHS P30 DK116074
6 · The paper itself

Abstract

objectiveTo provide a snapshot of the profile of adults and youth with type 1 diabetes (T1D) in the United States and assessment of longitudinal changes in T1D management and clinical outcomes in the T1D Exchange registry. RESEARCH DESIGN AND

methodsData on diabetes management and outcomes from 22,697 registry participants (age 1-93 years) were collected between 2016 and 2018 and compared with data collected in 2010-2012 for 25,529 registry participants.

resultsMean HbA1c in 2016-2018 increased from 65 mmol/mol at the age of 5 years to 78 mmol/mol between ages 15 and 18, with a decrease to 64 mmol/mol by age 28 and 58-63 mmol/mol beyond age 30. The American Diabetes Association (ADA) HbA1c goal of <58 mmol/mol for youth was achieved by only 17% and the goal of <53 mmol/mol for adults by only 21%. Mean HbA1c levels changed little between 2010-2012 and 2016-2018, except in adolescents who had a higher mean HbA1c in 2016-2018. Insulin pump use increased from 57% in 2010-2012 to 63% in 2016-2018. Continuous glucose monitoring (CGM) increased from 7% in 2010-2012 to 30% in 2016-2018, rising >10-fold in children <12 years old. HbA1c levels were lower in CGM users than nonusers. Severe hypoglycemia was most frequent in participants ≥50 years old and diabetic ketoacidosis was most common in adolescents and young adults. Racial differences were evident in use of pumps and CGM and HbA1c levels.

conclusionsData from the T1D Exchange registry demonstrate that only a minority of adults and youth with T1D in the United States achieve ADA goals for HbA1c.

Indexed as

Blood GlucoseAdolescentAdultAgedChildChild, PreschoolDiabetes Mellitus, Type 1Disease ManagementFemaleHumansHypoglycemic AgentsInsulinInsulin Infusion SystemsMaleMiddle AgedRegistriesBlood GlucoseHypoglycemic AgentsInsulinContinuous glucose monitor useInsulin pump use.T1D Exchange registry

Identifiers

PMID30657336
PMCPMC7061293
OpenAlexW2909166675

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

and 2 more above

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.